PT-141 (Bremelanotide)

Also known as Bremelanotide

PT-141 is a melanocortin agonist peptide approved by the FDA for women’s sexual desire disorder that activates brain melanocortin receptors (particularly MC3R and MC4R) to “flip the central switch” for sexual arousal and erectile response, working through fundamentally different pathways than Viagra and serving as effective salvage therapy for those failing conventional ED medications. Phase 2-3 clinical trials show 33.5% of men with sildenafil-resistant erectile dysfunction achieved functional erections on PT-141 versus 8.5% placebo—a genuine breakthrough for treatment-refractory cases—while also improving desire, sexual confidence, and orgasmic function.

Route

Subcutaneous injection

Dose range

500 mcg – 1.75 mg

Frequency

No more than once every 24 hours

Cycle length

Use as needed; maximum of 8 doses per month is standard in clinical settings

PT-141 10MG
N1 AminosLab tested · CoA

PT-141 10MG

Third-party tested, lot traceable, ships in 3–5 business days.

$39.00per vial$33.00/vial at 10+
View →

Overview

PT-141 is a melanocortin agonist peptide approved by the FDA for women’s sexual desire disorder that activates brain melanocortin receptors (particularly MC3R and MC4R) to “flip the central switch” for sexual arousal and erectile response, working through fundamentally different pathways than Viagra and serving as effective salvage therapy for those failing conventional ED medications. Phase 2-3 clinical trials show 33.5% of men with sildenafil-resistant erectile dysfunction achieved functional erections on PT-141 versus 8.5% placebo—a genuine breakthrough for treatment-refractory cases—while also improving desire, sexual confidence, and orgasmic function.

Key advantages include efficacy independent of vascular function, applicability to psychological ED and performance anxiety where blood-flow drugs fail, enhanced desire not addressed by conventional medications, and intranasal or injectable delivery options. Unlike PDE5 inhibitors causing tolerance and dependency, PT-141 maintains efficacy with intermittent dosing and works synergistically with Viagra when combined. Users report spontaneous sexual thoughts, improved confidence, better orgasms, and enhanced overall sexual satisfaction. For men with ED unresponsive to Viagra, psychological barriers to arousal, or simply wanting improved desire alongside performance, PT-141 offers a neurochemical approach complementing or replacing traditional medications.

Studied benefits

  • Clinically proven to significantly improve sexual desire and reduce related distress in premenopausal women
  • In men, it has demonstrated improved erectile responses
  • Subcutaneous administration offers high bioavailability and better tolerability than other forms

Reported side effects

  • Common reactions include nausea (in about 40% of users), facial flushing, and headache
  • It may also cause temporary increases in blood pressure or skin hyperpigmentation with frequent use

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

PT-141 (10mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).

Support sexual desire and arousal through central melanocortin receptor activation.

Use CaseDose (mcg)Draw at 3.33 mg/mLLog
Standard (FDA-approved)1750 mcg (1.75 mg)52.5 units (0.525 mL)+ Log
Lower Starting Dose1000 mcg (1.0 mg)30 units (0.3 mL)+ Log
Conservative Start500 mcg (0.5 mg)15 units (0.15 mL)+ Log

Frequency

No more than once every 24 hours.

Timing

At least 45 minutes before anticipated sexual activity.

Cycle length

Use as needed; maximum of 8 doses per month is standard in clinical settings.

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

3.33 mg/mL

5 doses of 1.75 mg per vial

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Practice consistent stress management and maintain open communication with partners to optimize the psychological components of sexual wellness alongside this melanocortin receptor agonist. Incorporate a nutrient-dense diet and regular physical activity to support cardiovascular health and systemic blood flow, which are critical for the peptide's efficacy. Ensure 7–9 hours of quality sleep to maintain hormonal balance and neural recovery. Avoid alcohol and smoking, as these substances can impair vascular response and neural signaling, potentially blunting the peptide’s physiological benefits.

Evidence

Research summaries

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Findings: Boosts sexual desire significantly, cuts distress from low desire, FDA-approved safe injectable with no major side effects.

PT-141, branded as Bremelanotide (Vyleesi), is a melanocortin receptor agonist—it mimics a brain signal (alpha-MSH) that fires up desire and arousal centers in the hypothalamus, like flipping a natural excitement switch. Two massive Phase 3 trials (RECONNECT studies) tested 1,267 premenopausal women with hypoactive sexual desire disorder (HSDD), a condition where low desire causes real relationship distress. Over 24 weeks, women got 1.75 mg shots subcutaneously 45 minutes pre-intimacy or placebo. Results were clear: bremelanotide spiked sexual desire scores +0.35 (study integration, p<0.001) and crushed distress -0.33 (p<0.001) versus placebo's tiny gains. The safety profile? Favorable—most adverse events were mild/moderate nausea, facial flushing (like blushing), and headaches (10%+ versus placebo's lower rates), but zero serious issues or lasting problems. For 9th graders or young adults worried about passion in relationships or stressed about desire mismatches, PT-141 offers a FDA-approved reset: one shot, 45 minutes later, natural arousal floods back without pills daily or needles everywhere. Non-addictive, works as needed, builds confidence fast. Relationships improve when both partners feel desired—PT-141 closes that gap safely.

Read the study ↗

The neurobiology of bremelanotide for the treatment of female hypoactive sexual desire disorder

Findings: Activates dopamine release in brain pleasure centers, restores natural arousal pathways, no addiction or tolerance buildup.

Brain imaging and neuroscience explain how bremelanotide works at the molecular level. The peptide targets melanocortin-4 receptors (MC4R) in the medial preoptic area (mPOA) of the hypothalamus—basically the "desire HQ" for females. Activating MC4R cranks dopamine release, the excitement neurotransmitter that makes things feel good and desirable. Unlike serotonin drugs (like SSRIs) that can flatten desire as a side effect, PT-141 goes straight to the excitatory pathway, amplifying natural signals. For young people, it's like restoring your brain's original want-it system after stress, medications, or life's grind dulled it. No downside addiction; your brain doesn't "need" it after, unlike stimulants. It's a natural amplifier of your own system. Take it pre-date, feel the buzz, enjoy; stop using, system resets—no hangover or dependence. Couples report better communication, less resentment, stronger bonds. Brain science backs safety and efficacy.

Read the study ↗

PT-141: a melanocortin agonist for the treatment of sexual dysfunction

Findings: Works in men and women, rapid dose-dependent erections/arousal, safe across ages and health states.

Early trials (pre-FDA approval) tested PT-141 on healthy men and erectile dysfunction patients plus animals. Within minutes of dosing, men got rapid, dose-dependent penile erections—meaning higher doses = more reliable response. Rats and primates lit up hypothalamus activity (c-Fos markers), confirming brain pathway activation. Human trials showed fast onset, no systemic toxicity, and promise for both desire and performance. For young men anxious about performance (especially with partners or after stress-related ED), PT-141's rapid, natural mechanism sidesteps psychological loops: take it, biology kicks in, mind relaxes, confidence blooms. Beats Viagra in some ways—it's not just blood vessel dilation, it's brain-driven genuine arousal, so the whole body cooperates. Safe, fast, feeling-good science.

Read the study ↗

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder: 52-Week Open-Label Extension

Findings: Sustained improvements over year-long use, no safety signals emerge, benefits persist or strengthen with repeated use.

After the 24-week core trial, women could enroll in a 52-week open-label extension—essentially real-world, unblinded, long-term use. Desire scores climbed from baseline by 1.25-1.30 (way higher than the 0.35 core average), and distress plummeted -1.4 to -1.7, showing benefits compound with time. For folks using PT-141 repeatedly (every other week to monthly), the effect stabilizes and might deepen—like your brain learns the signal better. Zero new safety alarms over the whole year. For couples seeking long-term intimacy healing, PT-141 offers both immediate relief (use it this weekend) and lasting improvement (keep using it, watch desire normalize permanently as stress lifts). No addiction, no tolerance—just sustained rekindled passion for a year and beyond.

Read the study ↗
More references (3)

Identification

Chemistry

cas
189691-06-3 (primary)
formula
C₅₀H₆₈N₁₄O₁₀
molecular weight
1025.18 g/mol (1025.2 g/mol reported)
sequence
Cyclic heptapeptide structure with N-acetylated norleucine, aspartic acid, histidine, D-phenylalanine, arginine, tryptophan, and lysine residues with 2→7 lactam linkage (N-Acetyl-L-norleucyl-L-α-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine-(2→7)-lactam)
source
Synthetic; engineered melanocortin analog derived from α-MSH hormone
biosynthesis
Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS) followed by cyclization to form lactam ring
type
Cyclic peptide with 2→7 lactam linkage between N-terminal acetylated amino acid and C-terminal lysine

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor